Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
Status:
Completed
Trial end date:
2021-02-04
Target enrollment:
Participant gender:
Summary
This is a Phase III, double-blind, randomized, multicenter study to compare the efficacy and
to evaluate the safety and immunogenicity of TX05 (trastuzumab) with Herceptin® in subjects
with HER2 positive early breast cancer.